Drugs / [11C]UCB-J
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05418608 | Apr 2022 → Apr 2024 | — | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT04311619 | Dec 2019 → Feb 2025 | major depressive disorder | Davidzon, Guido, M.D. | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05465538 | Jul 2022 → Dec 2026 expected | — | Yale University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [11C]UCB-J | “The investigators will conduct a PET study of the novel SV2A imaging tracer \[11C\]UCB-J in participants” NCT05418608 ↗ |
| Modality | Diagnostic / imaging agent | “radioactive positron emission tomography (PET) tracer \[11C\]UCB-J” NCT04311619 ↗ |
| Route | Intravenous | “I.V. bolus administration” NCT04311619 ↗ |